# JK08

Source: https://onco.cc/drugs/jk08/  
OnCo record `jk08` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JK08 is an experimental fusion protein or cytokine from Salubris Biotherapeutics in phase 2 trials for melanoma, colorectal cancer and non-small-cell lung cancer, aimed at CTLA-4.

## Summary

JK08 is a fusion protein or cytokine developed by Salubris Biotherapeutics. Its target is CTLA-4. ClinicalTrials.gov describes the intervention as: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma, colorectal cancer, non-small-cell lung cancer, bladder & urothelial cancer and head and neck squamous cell carcinoma. The largest, NCT05620134, plans to enrol 263 participants with primary completion was scheduled for 2025-10-17 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: fusion protein or cytokine
- Mechanism: Fusion protein or cytokine directed at CTLA-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Notes

- JK08 is a recombinant fusion protein of a fully human anti-CTLA-4 antibody with a complex of human IL-15 and the sushi domain of IL-15 receptor alpha, so it blocks a checkpoint and delivers a T-cell growth signal from the same molecule (registry intervention description, NCT05620134). The IL-15 half has no target record in the corpus.

## Sources

- ClinicalTrials.gov: trials of JK08: https://clinicaltrials.gov/search?intr=JK08
- ClinicalTrials.gov NCT05620134: https://clinicaltrials.gov/study/NCT05620134

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/)
- trials: [Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer](https://onco.cc/trials/nct05620134/)
- companies: [Salubris Biotherapeutics](https://onco.cc/companies/salubris-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/jk08.json